This NCPD activity, presented by Laura S. Wood, RN, MSN, OCN, discusses mechanisms of action of IO agents and VEGFR TKIs, efficacy and safety profiles of IO and VEGFR TKI therapies, and strategies to improve treatment tolerability for advanced renal cell carcinoma. Start now! 

This free online CME/NCPD activity on first-line and second-line treatment for advanced renal cell carcinoma is presented by Bradley McGregor, MD, and Robert Motzer, MD. It is also available as a podcast. Start the activity now!

In this virtual tumor board, Sara M. Tolaney, MD, MPH, Ira J. Bleiweiss, MD, and Mikel Ross, MSN, RN, AGPCNP-BC, OCN^®, CBCN, assess predictive and prognostic markers for MBC, evaluate current and emerging data on therapeutic approaches for HER2-positive, hormone receptor-positive/HER2-negative, and triple-negative MBC, and apply strategies to manage adverse events for MBC. Start now! 

This CME virtual tumor board, presented by Loretta J. Nastoupil, MD, Reem Karmali, MD, MS, and Francisco Vega, MD, PhD, evaluates emerging efficacy and safety data on novel therapeutic approaches, discusses the implications of POD24 status in therapeutic decision making for patients, and applies strategies to optimize treatment experiences and outcomes for patients with relapsed/refractory FL. Start now! 

In this virtual tumor board, Vicki L. Keedy, MD, MSCI, Brian P. Rubin, MD, PhD, and Kathleen Polson, NP, discuss diagnostic evaluation, treatment selection, and supportive care strategies for patients with soft tissue sarcoma.

This NCPD activity, presented by Allison Miller Imahiyerobo, APN, includes cases that provide insight into nursing management of ITP. In addition, Ms. Miller Imahiyerobo discusses the pathogenesis of ITP and differentiates the efficacy and safety profiles of current and emerging ITP therapies. 

In this NCPD activity, Amy L. Goodrich, RN, MSN, CRNP-AC, evaluates guideline recommendations for the management of patients with advanced NHL, assesses emerging efficacy and safety data on novel therapies for advanced NHL, and applies strategies to manage adverse events and optimize treatment experiences for patients receiving novel therapies for NHL. Start now!